Financial Comparison: Metagenomi (MGX) & The Competition

Metagenomi (NASDAQ:MGX) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Metagenomi to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, risk, profitability, dividends and valuation.

Profitability

This table compares Metagenomi and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metagenomi	-134.27%	-43.23%	-18.86%
Metagenomi Competitors	-2,185.76%	-161.46%	-40.62%

Volatility and Risk

Metagenomi has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Comparatively, Metagenomi’s rivals have a beta of -4.48, suggesting that their average stock price is 548% less volatile than the S&P 500.

Institutional & Insider Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Metagenomi and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metagenomi	$52.30 million	-$68.25 million	-0.64
Metagenomi Competitors	$575.27 million	-$70.96 million	-0.44

Metagenomi’s rivals have higher revenue, but lower earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and target prices for Metagenomi and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	0	1	4	0	2.80
Metagenomi Competitors	1961	5434	14026	300	2.58

Metagenomi currently has a consensus target price of $13.00, suggesting a potential upside of 678.44%. As a group, “Biological products, except diagnostic” companies have a potential upside of 130.13%. Given Metagenomi’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Metagenomi is more favorable than its rivals.

Summary

Metagenomi beats its rivals on 8 of the 13 factors compared.

Metagenomi Company Profile

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.